Journal: Nature Communications

Article Title: Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile

doi: 10.1038/s41467-025-59093-7

Figure Lengend Snippet: A Schematic diagram of fibrosis model establishment and treatment strategy in young or aged mice. B , C Young mouse BW changes ( B ) and survival curve ( C ) of control and BLM groups treated with IgG/ β LNP-FAPCAR 2.2, CD5/ β LNP-FAPCAR 2.2 (10 μg) and saline ( n = 10). The survival rate was analyzed using the log-rank (Mantel-Cox) test. D Lung coefficients (lung weight (mg)/BW (g)) ( n = 5,5,10,10,10,7). E tdTomato reporter gene expressed in T cells of spleen and lung at 24 h after the second CD5/ β LNP-FAPCAR 2.2 injection (Scar bar: 10 μm). F Flow cytometry plots for FAPCAR expression in CD3 + pulmonary T cells of BLM+Saline and CD5/ β LNP-FAPCAR 2.2 treatment groups and the ratio of FAPCAR expression to CD3 + pulmonary T cells ( n = 4). G Flow cytometry analysis of FAP + Pdgfra + fibroblasts in BLM+Saline and CD5/ β LNP-FAPCAR 2.2 treatment groups, ratio of FAP + Pdgfra + fibroblasts to all lung cells, and ratio of Pdgfra + fibroblasts (both FAP + and FAP — ) to all lung cells ( n = 4). H , I Representative micro-CT images and mean HU density ( H ), and lung air volume (mm 3 ) ( I ) computed according to CT results at postoperative 28 days ( n = 4,4,7,7,7,7). J Digital photos of lung tissue. ‘n’ means independent biological replications. The values are the means ± SDs. * P < 0.05. P -value determined by one-way ANOVA followed by Tukey’s multiple comparisons test ( D , F , H , I ) and two tailed unpaired Student’s t -test ( G ). (BW: body weight; HU: Hounsfield unit). Source data are provided as a Source Data file. Created in BioRender ( A , B ) .

Article Snippet: FVS 700 (live/death dye, #564997, BD Bioscience, CA, USA), CD3e (#562600, BD Bioscience), CD8a (#557654, BD Bioscience), F4/80 (#565411, BD Bioscience), CD86 (#558703, BD Bioscience), CD163 (#12-1631-82, Thermo Fisher), FAP (#FAB9727G, R&D system) and Pdgfra (#12-1401-81, Thermo Fisher) were used in experiments.

Techniques: Control, Saline, Injection, Flow Cytometry, Expressing, Micro-CT, Two Tailed Test

Journal: Histopathology

Article Title: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

doi: 10.1111/j.1365-2559.2009.03399.x

Figure Lengend Snippet: Immunohistochemistry in low-grade myofibroblastic sarcoma, showing strong positivity for both fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV). IgG1, negative control. Scale bar, 50 μm.

Article Snippet: Primary antibodies were mouse monoclonal anti-FAP (clone F19), rat monoclonal anti-FAP (clone D8) and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA).

Techniques: Immunohistochemistry, Activation Assay, Negative Control

Journal: Histopathology

Article Title: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

doi: 10.1111/j.1365-2559.2009.03399.x

Figure Lengend Snippet: Immunohistochemistry of a fibroblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV) are strongly positive. Scale bar, 25 μm.

Article Snippet: Primary antibodies were mouse monoclonal anti-FAP (clone F19), rat monoclonal anti-FAP (clone D8) and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA).

Techniques: Immunohistochemistry, Activation Assay

Journal: Histopathology

Article Title: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

doi: 10.1111/j.1365-2559.2009.03399.x

Figure Lengend Snippet: Immunohistochemistry of an osteoblastic area of an osteosarcoma. Fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV) are weakly positive in the osteoblastic area. Scale bar, 25 μm.

Article Snippet: Primary antibodies were mouse monoclonal anti-FAP (clone F19), rat monoclonal anti-FAP (clone D8) and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA).

Techniques: Immunohistochemistry, Activation Assay

Journal: Histopathology

Article Title: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

doi: 10.1111/j.1365-2559.2009.03399.x

Figure Lengend Snippet: Immunohistochemistry in Ewing’s sarcoma. Tumour cells, small and round in shape, are negative for fibroblast activation protein (FAP) and dipeptidylpeptidase-IV (DPP-IV). Stromal cells in septal areas are positive for FAP and DPP-IV (marked with a star). Scale bar, 50 μm.

Article Snippet: Primary antibodies were mouse monoclonal anti-FAP (clone F19), rat monoclonal anti-FAP (clone D8) and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA).

Techniques: Immunohistochemistry, Activation Assay

Journal: Histopathology

Article Title: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours

doi: 10.1111/j.1365-2559.2009.03399.x

Figure Lengend Snippet: Immunohistochemistry of a giant cell tumour. Fibroblast activation protein (FAP) is expressed in spindle-shaped fibroblastic cells, whereas dipeptidylpeptidase-IV (DPP-IV) is positive in giant cells. Scale bar, 25 μm.

Article Snippet: Primary antibodies were mouse monoclonal anti-FAP (clone F19), rat monoclonal anti-FAP (clone D8) and mouse monoclonal anti-DPP-IV (anti-CD26) (clone M-A261; Pharmingen, San Diego, CA, USA).

Techniques: Immunohistochemistry, Activation Assay

Journal: British Journal of Cancer

Article Title: Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity

doi: 10.1038/s41416-024-02639-1

Figure Lengend Snippet: a Tumor growth curve between MC38 + MEF tumors and MC38 tumor ( n = 7, means ± SEM; ** P < 0.01; Student’s t test on day 17). b Macroscopic image of harvested tumors. c Tumor weight between MC38 + MEF tumors and MC38 tumor ( n = 7, means ± SEM; ** P < 0.01; Student’s t test om day 17). d TGF-β secretion in supernatant from MEF or CAF MC38 via ELISA. e TGF-β secretion in tumor-bearing mice (MC38 or MC38 + MEF tumors) via ELISA. ( n = 7, means ± SEM; * P < 0.05; Student’s t test). f Immunohistochemical images of TGF-β in MC38 or MC38 + MEF tumors. Right images were magnified. Scale bar = 200 μm (left), 50 μm (right). g Quantification of TGF-β positive area index by Image J software. ( n = 7, means ± SEM; * P < 0.05; Student’s t test). Representative images of flow cytometry gated with FAP and PD-L1 ( h ) or CD73 ( i ). j , k Positive proportions of PD-L1 + cells ( j ) or CD73 + cells in FAP + cells for MEF or CAF MC38 cells by flow cytometry ( n = 5, means ± SEM; *** P < 0.001; Student’s t test). Representative examples from three experiments were presented in d – k .

Article Snippet: We used fluorescence antibody for PD-L1 (APC anti-mouse PD-L1 antibody, #124312, 1:100 dilution, BioLegend, Inc, San Diego, USA), CD73 (PerCP/Cyanine5.5 anti-mouse CD73 antibody, #127214, 1:100 dilution, BioLegend), FAP (HPAB-0171-CN, Creative Biolabs, Inc, New York, USA).

Techniques: Enzyme-linked Immunosorbent Assay, Immunohistochemical staining, Software, Flow Cytometry